ASLN - ASLAN's eblasakimab for atopic dermatitis effective with monthly dosing

2023-07-06 11:25:40 ET

• Top-line phase 2b results indicated that ASLAN Pharmaceuticals ( NASDAQ: ASLN ) eblasakimab was effective in treating atopic dermatitis when dosed monthly.
• Data showed that 600mg of eblasakimab dosed once every four weeks led to 62.7% of patients achieving EASI-75, while 34.1% reaching EASI-90. Both are measures of eczema's spread and severity.
• ASLAN ( ASLN ) said that the once monthly arm performed better than either the 400mg every two weeks or 300mg every two weeks arms.
• Eblasakimab targets the IL-13 receptor subunit of the Type 2 receptor, a key pathway involved in inflammatory diseases.
• CEO Carl Firth said the company is looking to quickly move the candidate into phase 3 .
• Seeking Alpha's Quant Rating views ASLAN ( ASLN ) as a hold.

For further details see: